AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.
TechCrunch·1h ago·Neutral
What Happened
10x Science, a newly founded startup, secured $4.8 million in seed funding to address a bottleneck in drug development. As AI generates numerous potential drug candidates, the company aims to characterize and test these compounds efficiently. Founded by biochemists David Roberts, Andrew Reiter, and AI expert Vishnu Tejas, 10x Science bridges the gap between AI prediction tools and practical pharmaceutical development requirements.
Key Entities
10x ScienceInitialized CapitalY CombinatorDavid RobertsAndrew ReiterVishnu TejasGoogle DeepMindKeytrudaMerckStanford